Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Autores: Lonial, S.; Richardson, P. G.; Popat, R.; Stadtmauer, E. A.; Larsen, J. T.; Oriol, A.; Knop, S.; Jagannath, S.; Cook, G.; Badros, A. Z.; Rodríguez Otero, Paula; Siegel, D. S.; Nguyen, T. V.; Micco, A.; Amin, A.; Chen, M.; Kueenburg, E.; van de Donk, N. W. C. J.